Primary central nervous system lymphomas

Česká verzia

Authors: M. Hrudková; D. Belada; L. Smolej; P. Žák; J. Malý
Authors place of work: Oddělení klinické hematologie II. interní kliniky Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MUDr. Jaroslav Malý, CSc.
Published in the journal: Vnitř Lék 2010; 56(8): 795-800
Category: Reviews

Summary

Primary central nervous system lymphoma (PCNSL) is a rare form of extranodal lymphoma (nearly always non‑Hodgkin’s) and accounts for approximately 3 to 4% of primary brain tumors. PCNSL typically affects patients older than 60 years. Clinical features are variable and reflect the location of central nervous system lesion. Magnetic resonance imaging and stereotactic biopsy are the most important tools for diagnostic assessment. Chemotherapy based on high‑dose of methotrexate (HD‑MTX) and whole brain radiotherapy are the cornerstones of treatment. Radiotherapy is usually omitted in individuals older than 60 years because of high risk of unacceptable delayed neurotoxicity. Treatment of PCNSL should be started as soon as possible after diagnosis because delay in treatment may shorten the patients’ survival.

Key words:
primary central nervous system lymphoma – chemotherapy – methotrexate – radiotherapy – neurotoxicity

Zdroje

1. Kluin PM, Ko YH, Kovrigina AM et al. World Health Organisation classification of tumors of haematopoietic and lymphoid tissue. Lyon: IARC Press 2008.

2. Singh AD, Lewis H, Schachat AP. Primary lymphoma of the central nervous system. Ophthalmol Clin North Am 2005; 18: 199–207.

3. Hoang‑Xuan K, Camilleri‑Broët S, Soussain C. Recent advances in primary CNS lymphoma. Curr Opin Oncol 2004; 16: 601–606.

4. Hochberg FH, Baehring JM, Hochberg EP. Primary CNS lymphoma. Nat Clin Pract Neurol 2007; 3: 24–35.

5. Commins DL. Pathology of primary central nervous system lymphoma. Neurosurg Focus 2006; 21: E2.

6. Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol 2006; 24: 1281–1288.

7. Fitzsimmons A, Upchurch K, Batchelor T. Clinical features and diagnosis of primary central nervous system lymphoma. Hematol Oncol Clin North Am 2005; 19: 689–703.

8. Eichler AF, Batchelor TT. Primary central nervous system lymphoma: presentation, diagnosis and staging. Neurosurg Focus 2006; 21: E15.

9. Morris PG, Abrey LE. Therapeutic challenges in primary CNS lymphoma. Lancet Neurol 2009; 8: 581–592.

10. Říhová E, Šišková A, Jandusová J et al. Nitrooční lymfom – klinická studie14 pacientů s NHL. Cesk Slov Oftalmol 2004; 60: 3–16.

11. Ferreri AJ, Reni M. Primary central nervous system lymphoma. Crit Rev Oncol Hematol 2007; 63: 257–268.

12. Almhanna K, Wongchaowart N, Sweetenham J. Intracerebral Hodgkin’s lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma: a case report and literature review. Cancer Invest 2009; 27: 215–220.

13. Ferreri AJ, Blay JY, Reni M et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003; 21: 266–272.

14. Go JL, Lee SC, Kim PE. Imaging of primary central nervous system lymphoma. Neurosurg Focus 2006; 21: E4.

15. Mohile NA, DeAngelis LM, Abrey LE. Utility of brain FDG‑PET in primary CNS lymphoma. Clin Adv Hematol Oncol 2008; 6: 818–820.

16. Gerstner E, Batchelor T. Primary CNS lymphoma. Expert Rev Anticancer Ther 2007; 7: 689–700.

17. Klabusay M, Pevná M, Kissová J et al. Vzácná diagnóza: CD4+56+ leukémie z dendritických buněk typu DC2. Čas Lék Česk 2009; 147: 511–515.

18. Shah GD, DeAngelis LM. Treatment of primary central nervous system lymphoma. Hematol Oncol Clin North Am 2005; 19: 611–627.

19. Ferreri AJ, Reni M. Prognostic factors in primary central nervous system lymphomas. Hematol Oncol Clin North Am 2005; 19: 629–649.

20. Cady FM, O’Neill BP, Law ME et al. Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course. J Clin Oncol 2008; 26: 4814–4819.

21. Tun HW, Personett D, Baskerville KA et al. Pathway analysis of primary central nervous system lymphoma. Blood 2008; 111: 3200–3210.

22. DeAngelis LM, Hormigo A. Treatment of primary central nervous system lymphoma. Semin Oncol 2004; 31: 684–692.

23. DeAngelis LM, Iwamoto FM. An update on therapy of primary central nervous system lymphoma. Hematology Am Soc Hematol Educ Program 2006: 311–316.

24. Abrey LE. Controversies in primary CNS lymphoma. Expert Rev Neurother 2005; 5: 459–464.

25. Lachance DH, Brizel DM, Gockerman JP et al. Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: short‑duration response and multifocal intracerebral recurrence preceding radiotherapy. Neurology 1994; 44: 1721–1727.

26. Schultz C, Scott C, Sherman W et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88–06. J Clin Oncol 1996; 14: 556–564.

27. Ekenel M, Iwamoto FM, Ben‑Porat LS et al. Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high‑dose methotrexate‑based chemotherapy. Cancer 2008; 113: 1025–1031.

28. Bessell EM, López‑Guillermo A, Villá Set al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol 2002; 20: 231–236.

29. Belada D, Smolej L, Štěpanková P et al. Dosažení Bcl‑2/IgH negativity v periferní krvi/kostní dřeni po léčbě je u nemocných s folikulárním lymfomem spojeno s lepší prognózou onemocnění. Vnitř Lék 2007; 53: 1057–1063.

30. Soussain C, Hoang‑Xuan K, Doolittle ND. New treatment approaches in primary central nervous system lymphoma. Hematol Oncol Clin North Am 2005; 19: 719–728.

31. Shah GD, Yahalom J, Correa DD et al. Combined immunochemotherapy with reduced whole‑brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 2007; 25: 4730–4735.

32. Hong SJ, Kim JS, Chang JH et al. A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high‑dose chemotherapy with autologous stem cell rescue. Yonsei Med J 2009; 50: 280–283.

33. Aboulafia DM, Ratner L, Miles SA et al. Antiviral and immunomodulatory treatment for AIDS‑related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019. Clin Lymphoma Myeloma 2006; 6: 399–402.

34. Kreisl TN, Panageas KS, Elkin EB et al. Treatment patterns and prognosis in patients with human immunodeficiency virus and primary central system lymphoma. Leuk Lymphoma 2008; 49: 1710–1716.

35. Parekh S, Ratech H, Sparano JA. Human immunodeficiency virus‑associated lymphoma. Clin Adv Hematol Oncol 2003; 1: 295–301.

36. Belada D, Trněný M, Campr V et al. Diagnostické a léčebné postupy u nemocných s maligními lymfomy III. 4th ed. Hradec Králové: HK Credit 2009: 30–36.